{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:20:02Z","timestamp":1780597202748,"version":"3.54.1"},"reference-count":16,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T00:00:00Z","timestamp":1606608000000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,11,2]]},"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:p>Heavy chain disease (HCD) is a rare B-cell proliferative neoplasm that is characterised by the production of truncated monoclonal immunoglobulin heavy chains without light chains. Gamma HCD is a subgroup of HCD. A 67-year-old man was admitted to our hospital with dyspnoea and lower leg oedema. Based on the results of heart catheterisation, he was diagnosed with pulmonary hypertension. Laboratory tests revealed an elevated level of IgG, and serum immunoelectrophoresis showed that IgG was a monoclonal gamma heavy chain without light chains. Finally, he was diagnosed with gamma HCD complicated by pulmonary hypertension. Bortezomib and dexamethasone therapy was initiated, but became refractory within 8\u2009months. Therefore, the treatment was switched to lenalidomide and dexamethasone therapy, and the disease has been stably controlled for more than 2 years. To the best of our knowledge, this is the first case of gamma HCD being successfully treated by lenalidomide and dexamethasone therapy.<\/jats:p>","DOI":"10.1136\/bcr-2020-236162","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T15:45:45Z","timestamp":1606751145000},"page":"e236162","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Gamma heavy chain disease complicated by pulmonary hypertension, which was successfully treated with lenalidomide"],"prefix":"10.1136","volume":"13","author":[{"given":"Sho","family":"Shibata","sequence":"first","affiliation":[{"name":"Hematology, Tazuke Kofukai, Medical Research Institute, Kitano Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Fukunaga","sequence":"additional","affiliation":[{"name":"Hematology, Tazuke Kofukai, Medical Research Institute, Kitano Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"2025082800301550000_13.11.e236162.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2005.01.029"},{"key":"2025082800301550000_13.11.e236162.2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(64)90191-3"},{"key":"2025082800301550000_13.11.e236162.3","unstructured":"Cook JR , Harris NL , Isaacson PG , et al . Heavy chain diseases; who classification of tumours of haematopoietic and lymphoid tissues, world Health organization. 4 edn. France: International Agency for Research on Cancer, 2017: 237\u201340."},{"key":"2025082800301550000_13.11.e236162.4","first-page":"45","article-title":"The heavy chain diseases: clinical and pathologic features","volume":"28","author":"Bianchi","year":"2014","journal-title":"Oncology"},{"key":"2025082800301550000_13.11.e236162.5","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200307000-00002"},{"key":"2025082800301550000_13.11.e236162.6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00005792-198911000-00001","article-title":"Gamma heavy chain \"disease\": heterogeneity of the clinicopathologic features. Report of 16 cases and review of the literature","volume":"68","author":"Fermand","year":"1989","journal-title":"Medicine"},{"key":"2025082800301550000_13.11.e236162.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.029"},{"key":"2025082800301550000_13.11.e236162.8","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4330\/wjc.v8.i12.703","article-title":"Hematological disorders and pulmonary hypertension","volume":"8","author":"Mathew","year":"2016","journal-title":"World J Cardiol"},{"key":"2025082800301550000_13.11.e236162.9","doi-asserted-by":"publisher","DOI":"10.2174\/156652408786241447"},{"key":"2025082800301550000_13.11.e236162.10","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1164\/rccm.201502-0407OC","article-title":"Bone marrow-derived cells contribute to the pathogenesis of pulmonary arterial hypertension","volume":"193","author":"Yan","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2025082800301550000_13.11.e236162.11","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1086\/682430","article-title":"Pulmonary hypertension complicating multiple myeloma","volume":"5","author":"Krishnan","year":"2015","journal-title":"Pulm Circ"},{"key":"2025082800301550000_13.11.e236162.12","first-page":"15391","article-title":"Pulmonary arterial hypertension due to pulmonary vascular amyloid deposition in a patient with multiple myeloma","volume":"8","author":"Hashimoto","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"2025082800301550000_13.11.e236162.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcpc0800959"},{"key":"2025082800301550000_13.11.e236162.14","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ajh.21284","article-title":"Combination of rituximab and chemotherapy showing anti-tumor effect in gamma heavy chain disease expressing CD20","volume":"83","author":"Takano","year":"2008","journal-title":"Am J Hematol"},{"key":"2025082800301550000_13.11.e236162.15","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.5051.5051","article-title":"Induction therapy for gamma-heavy chain disease with bortezomib and dexamethasone: a case report","volume":"120","author":"Arnason","year":"2012","journal-title":"Blood"},{"key":"2025082800301550000_13.11.e236162.16","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1080\/13543784.2016.1208170","article-title":"Lenalidomide for the treatment of B-cell lymphoma","volume":"25","author":"Garciaz","year":"2016","journal-title":"Expert Opin Investig Drugs"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-236162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:30:23Z","timestamp":1756366223000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-236162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":16,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,30]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/bcr-2020-236162"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-236162","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}